Joana S. Rodrigues

Joana S. Rodrigues

Auto-generated profile, based on publicly available information

Joana S. Rodrigues

Neoplasia & Endocrine Differentiation, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), University of Santiago de Compostela (USC), Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2012 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
CAClara V Alvarez
Clara V Alvarez
MGMontserrat Garcia-Lavandeira
Montserrat Garcia-Lavandeira
MGMaria E R Garcia-Rendueles
Maria E R Garcia-Rendueles
EDEsther Diaz-Rodriguez
Esther Diaz-Rodriguez
AGAngela R Garcia-Rendueles
Angela R Garcia-Rendueles
SLSusana Belen Bravo López
Susana Belen Bravo López
Embryonic, adult, artificially reprogrammed, and cancer…– there are various types of cells associated with stemness. Do they have something fundamental in common? Are we applying a common name to very different entities? In this review, we will revisit the characteristics that define ‘pluripotency’, the main property of stem cells (SCs). For each main type of physiological (embryonic and adult) or synthetic (induced pluripotent) SCs, markers and functional behavior in vitro and in vivo will be described. We will review the pioneering work that has led to obtaining human SC lines, together with the problems that have arisen, both in a biological context (DNA alterations, heterogeneity, tumors, and immunogenicity) and with regard to ethical concerns. Such problems have led to proposals for new operative procedures for growing human SCs of sufficiently high quality for use as models of disease and in human therapy. Finally, we will review the data from the first clinical trials to use various types of SCs.

25 July 2016 in Oncogene
Verified
Journal Article
Closed access
AGA R Garcia-Rendueles
A R Garcia-Rendueles
JRJ S Rodrigues
J S Rodrigues
MGM E R Garcia-Rendueles
M E R Garcia-Rendueles
MSM Suarez-Fariña
M Suarez-Fariña
SPS Perez-Romero
S Perez-Romero
CAClara V Alvarez
Clara V Alvarez

5 February 2015 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
MGMontserrat Garcia-Lavandeira
Montserrat Garcia-Lavandeira
EDEsther Diaz-Rodriguez
Esther Diaz-Rodriguez
DBDilek Bahar
Dilek Bahar
AGAngela R. Garcia-Rendueles
Angela R. Garcia-Rendueles
JRJoana S. Rodrigues
Joana S. Rodrigues
CAClara V Alvarez
Clara V Alvarez
The recent demonstration using genetic tracing that in the adult pituitary stem cells are normally recruited from the niche in the marginal zone and differentiate into secretory cells in the adenopituitary has elegantly confirmed the proposal made when the pituitary stem cell niche was first discovered 5 years ago. Some of the early controversies have also been resolved. However, many questions remain, such as which are the markers that make a pituitary stem cell truly unique and the exact mechanisms that trigger recruitment from the niche. Little is known about the processes of commitment and differentiation once a stem cell has left the niche. Moreover, the acceptance that pituitary cells are renewed by stem cells implies the existence of regulated mechanisms of cell death in differentiated cells which must themselves be explained. The demonstration of an apoptotic pathway mediated by RET/caspase 3/Pit-1/Arf/p53 in normal somatotrophs is therefore an important step towards understanding how pituitary cell number is regulated. Further work will elucidate how the rates of the three processes of cell renewal, differentiation and apoptosis are balanced in tissue homeostasis after birth, but altered in pituitary hyperplasia in response to physiological stimuli such as puberty and lactation. Thus, we can aim to understand the mechanisms underlying human disease due to insufficient (hypopituitarism) or excess (pituitary tumor) cell numbers.

1 June 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SLSusana Belen Bravo López
Susana Belen Bravo López
MGMaria E. R. Garcia-Rendueles
Maria E. R. Garcia-Rendueles
AGAngela R. Garcia-Rendueles
Angela R. Garcia-Rendueles
JRJoana S. Rodrigues
Joana S. Rodrigues
SPSihara Perez-Romero
Sihara Perez-Romero
CAClara V Alvarez
Clara V Alvarez
Mechanisms of thyroid physiology and cancer are principally studied in follicular cell lines. However, human thyroid cancer lines were found to be heavily contaminated by other sources, and only one supposedly normal-thyroid cell line, immortalized with SV40 antigen, is available. In primary culture, human follicular cultures lose their phenotype after passage. We hypothesized that the loss of the thyroid phenotype could be related to culture conditions in which human cells are grown in medium optimized for rodent culture, including hormones with marked differences in its affinity for the relevant rodent/human receptor. The objective of the study was to define conditions that allow the proliferation of primary human follicular thyrocytes for many passages without losing phenotype. Concentrations of hormones, transferrin, iodine, oligoelements, antioxidants, metabolites, and ethanol were adjusted within normal homeostatic human serum ranges. Single cultures were identified by short tandem repeats. Human-rodent interspecies contamination was assessed. We defined an humanized 7 homeostatic additives medium enabling growth of human thyroid cultures for more than 20 passages maintaining thyrocyte phenotype. Thyrocytes proliferated and were grouped as follicle-like structures; expressed Na+/I- symporter, pendrin, cytokeratins, thyroglobulin, and thyroperoxidase showed iodine-uptake and secreted thyroglobulin and free T3. Using these conditions, we generated a bank of thyroid tumors in culture from normal thyroids, Grave's hyperplasias, benign neoplasms (goiter, adenomas), and carcinomas. Using appropriate culture conditions is essential for phenotype maintenance in human thyrocytes. The bank of thyroid tumors in culture generated under humanized humanized 7 homeostatic additives culture conditions will provide a much-needed tool to compare similarly growing cells from normal vs pathological origins and thus to elucidate the molecular basis of thyroid disease.

5 July 2010
Verified
Book Chapter
Closed access
MGMontserrat Garcia-Lavandeira
Montserrat Garcia-Lavandeira
EDEsther Diaz-Rodriguez
Esther Diaz-Rodriguez
MGMaria E.R. Garcia-Rendueles
Maria E.R. Garcia-Rendueles
JRJoana S. Rodrigues
Joana S. Rodrigues
SPSihara Perez-Romero
Sihara Perez-Romero
CAClara V Alvarez
Clara V Alvarez
The RET receptor is a tyrosine kinase receptor implicated in kidney and neural development. In the adenopituitary RET and the co-receptor GFRa1 are expressed exclusively in the somatotrophs secreting GH. RET is implicated in a clever pathway to maintain at physiological levels the number of somatotrophs and the GH production. Thus, in absence of its ligand GDNF, RET induces apoptosis through massive expression of Pit-1 leading to p53 accumulation. In the presence of the ligand GDNF, RET activates its tyrosine kinase and promotes survival at the expense of reducing Pit-1 expression and downregulating GH. Recent data suggest that RET can also have a second role in pituitary plasticity through a second co-receptor GFRa2.

14 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JRJoana S. Rodrigues
Joana S. Rodrigues
MCMiguel Chenlo
Miguel Chenlo
SLSusana Belen Bravo López
Susana Belen Bravo López
SPSihara Perez-Romero
Sihara Perez-Romero
MSMaria Suarez-Fariña
Maria Suarez-Fariña
CAClara V Alvarez
Clara V Alvarez
The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA–directed RNA interference (PIAS2b-dsRNAi) specifically inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi as a promising therapy for ATC and other aggressive anaplastic carcinomas.